Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Bone pain, COVID-19, Lymphadenopathy, Mobility decreased
Clinical narrative: COVID-19; Couldn't put arms down; Bone pain felt like they were splitting; Enlarged Lymph nodes under arm and breast; 104 fever; Nausea; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19), MOBILITY DECREASED (Couldn't put arms down), BONE PAIN (Bone pain felt like they were splitting), LYMPHADENOPATHY (Enlarged Lymph nodes under arm and breast) and PYREXIA (104 fever) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19), MOBILITY DECREASED (Couldn't put arms down), BONE PAIN (Bone pain felt like they were splitting), LYMPHADENOPATHY (Enlarged Lymph nodes under arm and breast), PYREXIA (104 fever) and NAUSEA (Nausea). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 25-Aug-2022 to 26-Aug-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19), MOBILITY DECREASED (Couldn't put arms down), BONE PAIN (Bone pain felt like they were splitting), LYMPHADENOPATHY (Enlarged Lymph nodes under arm and breast), PYREXIA (104 fever) and NAUSEA (Nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 104.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   The patient's ethnicity was reported.  No concomitant medications were reported.  The expiry date of paxlovid was reported as Feb-2023. The batch number of paxlovid was reported as 2815213. It was reported that paxlovid was discontinued permanently as patient's tongue was kind of tingling but her lips were going numb and tingling.She also had burning sensation inside the mouth. Further patient reported that her tongue was a little more worse than it was before. The patient had took 2 doses of paxlovid previous day and 1 dose that day. It was reported that paxlovid had altered her sense of taste. The strength of paxlovid was reported ad 300mg and 100mg dose pack. The dosage for paxlovid was reported as three tablets in the morning and three tablets at night.She woke up with nausea with the moderna first one and low grade fever. She had fever 101 with Moderna second one. clarified that she had nausea with all three moderna doses.She had a reaction to Moderna three shots. Caller clarified all three Covid shots were manufactured by Moderna. She had a reaction to all but with the third one she had 104 fever, bone pain that felt like they were splitting, enlarged lymph nodes under arm and breast, couldn't put arms down, and nausea. The patient had nausea and fever after all three Moderna Covid-19 vaccines.  Company comment- This spontaneous case concerns a 75-year-old female patient with no reported medical history, who experienced unexpected, non-serious AESI Covid-19, which occurred at an unknown time with regards to vaccination with a third dose of mRNA-1273. No further information was provided. The outcome of the event was reported as unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-636763.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a 75-year-old female patient with no reported medical history, who experienced unexpected, non-serious AESI Covid-19, which occurred at an unknown time with regards to vaccination with a third dose of mRNA-1273. No further information was provided. The outcome of the event was reported as unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.